Celsion Corporation is a fully integrated biopharmaceutical company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Our lead product candidate is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase 3 trial combined with RFA for the treatment of hepatocellular carcinoma. It is also in a phase 2 study for the treatment of recurrent chest wall breast cancer. Second in our pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian cancer.
Celsion has 3 platform technologies providing the basis for the development of a range of therapeutics for difficult-to-treat forms of cancers. With these technologies we are working to develop and commercialize more efficient, effective, and targeted oncology therapies, maximizing efficacy while minimizing side effects common to cancer treatments.

Show more
Type
Public
HQ
Trenton, US
Founded
1982
Size (employees)
19 (est)
Celsion was founded in 1982 and is headquartered in Trenton, US
Report incorrect company information

Key People/Management at Celsion

Michael H. Tardugno

Michael H. Tardugno

President and Chief Executive Officer
Jeffrey W. Church

Jeffrey W. Church

Senior Vice President, Corporate Business Strategy and Investor Relations
Nicholas Borys M.D.

Nicholas Borys M.D.

Vice President and Chief Medical Officer

Celsion Office Locations

Celsion has an office in Trenton
Trenton, US (HQ)
997 Lenox Dr
Show all (1)
Report incorrect company information

Celsion Financials and Metrics

Celsion Financials

Celsion's revenue was reported to be $500 k in FY, 2017
USD

Revenue (Q1, 2018)

125 k

Net income (Q1, 2018)

(4.5 m)

EBIT (Q1, 2018)

(4.3 m)

Market capitalization (22-Jun-2018)

57.7 m

Closing share price (22-Jun-2018)

3.3

Cash (31-Mar-2018)

2.3 m
Celsion's current market capitalization is $57.7 m.
Annual
USDFY, 2016FY, 2017

Revenue

500 k

General and administrative expense

6.5 m5.9 m

R&D expense

14.6 m13.1 m

Operating expense total

21.1 m19 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Revenue

125 k125 k

General and administrative expense

2.3 m2 m2 m1.8 m1.5 m1.9 m1.5 m1.5 m1.5 m1.2 m1.7 m

R&D expense

3.2 m4.6 m4.5 m3.6 m2.9 m3.4 m3.3 m4.2 m3.5 m3.3 m2.7 m

Operating expense total

5.5 m6.7 m6.5 m5.4 m4.4 m5.3 m4.9 m5.7 m4.9 m4.5 m4.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

5.7 m12.7 m9.3 m2.6 m11.4 m

Accounts Receivable

Inventories

Current Assets

4.5 m24.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018

Cash

9.6 m4.6 m7.6 m12 m7.6 m14.3 m12.3 m4.2 m4.5 m2.7 m2.3 m

Current Assets

50.5 m44.5 m30.7 m31.5 m24.8 m2.8 m20.9 m

PP&E

142.9 k(175.1 k)

Goodwill

1.9 m2 m2 m2 m2 m2 m2 m2 m2 m2 m2 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8.3 m)(25.5 m)(22.5 m)(22.1 m)(20.4 m)

Depreciation and Amortization

339.2 k369.3 k425 k1 m553 k

Inventories

77.5 k246.4 k

Accounts Payable

(887.3 k)1.8 m(859.2 k)48.8 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(6.7 m)(6.9 m)(7 m)(5.7 m)(4.3 m)(5.7 m)(4.5 m)(6.4 m)(5.2 m)(4.5 m)

Depreciation and Amortization

87.2 k

Accounts Payable

3.6 m4.4 m(565.9 k)

Purchases of PP&E

(29.6 k)
USDY, 2018

Financial Leverage

1.9 x
Show all financial metrics
Report incorrect company information

Celsion News and Updates

Report incorrect company information